Linked Life Data

19558553

Source:http://linkedlifedata.com/resource/pubmed/id/19558553

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-10-27
pubmed:abstractText
The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and hepatocellular carcinoma by offering better clinical responses. However, sorafenib and sunitinib are commonly associated with cutaneous toxicity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1365-2133
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
161
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1045-51
pubmed:meshHeading
pubmed-meshheading:19558553-Administration, Oral, pubmed-meshheading:19558553-Adult, pubmed-meshheading:19558553-Aged, pubmed-meshheading:19558553-Aged, 80 and over, pubmed-meshheading:19558553-Alopecia, pubmed-meshheading:19558553-Antineoplastic Agents, pubmed-meshheading:19558553-Benzenesulfonates, pubmed-meshheading:19558553-Carcinoma, Hepatocellular, pubmed-meshheading:19558553-Carcinoma, Renal Cell, pubmed-meshheading:19558553-Drug Eruptions, pubmed-meshheading:19558553-Female, pubmed-meshheading:19558553-Foot Dermatoses, pubmed-meshheading:19558553-Gastrointestinal Stromal Tumors, pubmed-meshheading:19558553-Hand Dermatoses, pubmed-meshheading:19558553-Humans, pubmed-meshheading:19558553-Indoles, pubmed-meshheading:19558553-Kidney Neoplasms, pubmed-meshheading:19558553-Male, pubmed-meshheading:19558553-Middle Aged, pubmed-meshheading:19558553-Protein Kinase Inhibitors, pubmed-meshheading:19558553-Pyridines, pubmed-meshheading:19558553-Pyrroles, pubmed-meshheading:19558553-Retrospective Studies, pubmed-meshheading:19558553-Skin Diseases, pubmed-meshheading:19558553-Stomatitis, pubmed-meshheading:19558553-Young Adult
pubmed:year
2009
pubmed:articleTitle
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
pubmed:affiliation
Departments of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong, Songpagu, Seoul 138-736, Korea.
pubmed:publicationType
Journal Article